A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors

Study Summary

The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with select advanced or metastatic solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.

Conditions

Metastatic Solid Tumor Recurrent Solid Tumor Advanced Solid Tumor Urinary Bladder Neoplasm Triple Negative Breast Cancer Non-small Cell Lung Cancer Esophageal Cancer Pancreatic Cancer Ovarian Cancer Cervical Cancer Head and Neck Squamous Cell Carcinoma Prostate Cancer Renal Pelvis Cancer Bladder Cancer

Interventions / Drugs

LY4101174

View on ClinicalTrials.gov ↗

Sponsor

LLY

Eli Lilly and Company

Diabetes/Oncology

C53/100

Study Details

Enrollment490 participants

Primary Completion—

Lead SponsorEli Lilly and Company

Data Retrieved2026-04-11 02:55:33.866924+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.